Measurement of minimal residual disease (MRD) following treatment of blood cancers is recognized as an important tool for disease management, and MRD negativity is increasingly a benchmark in clinical ...
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced the initiation of a new ...
MRD negativity in MM patients correlates with improved survival, suggesting its potential as a surrogate marker for survival outcomes. Novel therapeutics complicate the assessment of PFS and OS, ...
Marija Balic, MD, discusses the design and mechanism of the Oncodetect tumor-informed circulating tumor DNA assay for ...
Racial and Ethnic Disparities in Cancer Survival: The Contribution of Tumor, Sociodemographic, Institutional, and Neighborhood Characteristics Minimal residual disease (MRD) and genetic abnormalities ...
Over the past decade, minimal residual disease (MRD) has emerged as a crucial biomarker in multiple myeloma (MM) clinical trials, with MRD-negative status strongly linked to better clinical responses ...
Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...
Darzalex addition to VRd improved MRD negativity and PFS in transplant-ineligible multiple myeloma patients. The CEPHEUS trial showed a 50% increase in MRD negativity with Darzalex, consistent across ...
Management reaffirmed that the ALPHA3 futility analysis and MRD conversion data will be shared in the first half of 2026. The company expects 2025 cash burn of approximately $150 million and full-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback